Home / 0RU5.L / Company Profile

Oncoinvent ASA

0RU5.L | Healthcare | LSE
🌐 Website 📊 Reports 📈 Financials
$0.57
-0.03 (-5.62%)

Key Metrics

Market Cap
$22.32M
P/E Ratio
-0.16
EPS
$-3.50
Beta
N/A
Dividend Yield
N/A
ROE
-113.42%
Current Ratio
4.39

Company Information

Industry
Medical Pharmaceuticals

About Oncoinvent ASA

Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy It focuses on developing a pipeline of AXL kinase inhibitors Its lead product bemcentinib is a selective and orally bioavailable small molecule AXL inhibitor The company was founded by James Bradley Lorens and David R Micklem on December 21 2007 and is headquartered in Bergen Norway

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-02-26 $-1.09 $-1.09 +0.0%
2024-11-13 $-0.63 $-1.34 +-52.6%
2024-08-21 $-1.39 $-1.25 10.9%
2024-05-29 $-1.34 $-2.00 +-32.8%

Financial Ratios (TTM)

Gross Margin
98.06%
Operating Margin
-2,133.21%
Net Margin
-1,990.43%
ROA
-124.01%
Price to Book
0.68
Price to Sales
8.46